The result is very promising to me, especially in triple negatives. Even if GPNMB testing/selection was biased, the triple negative cases showed (even though small sample size) the drug hit the target - patients at this stage usually with confirmed triple negative status already.
I hope CLDX finds a bigger partner before moving to ph3. Triple negative is unmet need, not much competition there. They can explore trials in both earlier and later stage BC.
Market Data 
Markets 
AI
